Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Qkine logo — High quality and novel growth factors for stem cell and orga...

Qkine

High quality and novel growth factors for stem cell and organoid culture, regenerative medicine and cellular agriculture

Founded 2016 United Kingdom Cambridge, United Kingdom 40 employees Series B Total: $6.37M Biotechnology, Life Sciences

General Information

Company Name Qkine
Founded Year 2016
Location United Kingdom Cambridge, United Kingdom
Employees 40
Industries Biotechnology, Life Sciences
Funding Stage Series B
Social

BounceWatch is an independent company data service, not affiliated with Qkine. To contact Qkine, visit qkine.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Qkine compare?

A PDF of Qkine and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Qkine soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Qkine

Qkine is a biotechnology startup based in the United Kingdom, founded in 2016. The company specializes in manufacturing high-quality and novel growth factors for various applications including stem cell and organoid culture, regenerative medicine, and cellular agriculture. Qkine's products are aimed at supporting scientists in developing and scaling applications in these fields. The company also focuses on developing new growth factor technologies to cater to emerging fields such as cultured meat and 3D cell culture. Qkine's competitive edge lies in its proprietary technology developed in the laboratory of Dr. Marko Hyvönen, senior group leader at the University of Cambridge, which enables the manufacturing of highly pure bioactive recombinant proteins. Notably, the company sets a new benchmark for protein purity and utilizes protein engineering techniques to address biological and scalability challenges in the stem cell and regenerative medicine sector. This includes the development of optimized R-spondins to replace conditioned media for organoid culture. The company's commitment to quality is evident in its manufacturing process, conducted in a dedicated animal-derived component-free (ADCF) laboratory under an ISO 9001:2015 certification. Qkine also defines rigorous quality criteria, backed by detailed data and extensive quality testing on every lot to ensure reproducibility. The recent £4.30M Series B investment on 15 December 2022, led by Parkwalk Advisors, Downing Ventures, o2h Ventures, and Cambridge Angels group, speaks to the confidence that investors have in Qkine's potential to make a significant impact in the biotechnology and life sciences industries. For more information, visit www.qkine.com or contact the Qkine Team at [email protected].

Business keywords: Biologically active proteins, Protein purification, Stem cell culture, Regenerative medicine, Cellular agriculture, Animal-free growth factors, Organoid culture, Protein engineering, ISO 9001:2015 certified, Thermostable FGF-2, TGF beta 1 for stem cell media, HGF (NK1), Cambridge Science Park, Research and development, Recombinant proteins

Services & Products

Manufacturing bioactive proteins
Developing unique optimized proteins
Sustainable protein production

Target Customers

Research institutions Biotechnology companies Pharmaceutical companies Academic laboratories

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Series B £4.30M 4
Parkwalk Advisors Downing Ventures o2h Ventures
Parkwalk Advisors, Downing Ventures +2
15 Dec 2022
Series A £1.50M 5
Parkwalk Advisors Martlet Capital o2h Ventures
Parkwalk Advisors, Martlet Capital +3
08 Jun 2020
Seed Round £550.00K 1
Jim Warwick
03 Jun 2019
Grant £20.00K -
12 Jul 2018
Seed Round Undisclosed -
02 May 2018

Qkine Alternatives & Competitors

Qkine vs
Platome Biotechnology
Platome Biotechnology Iceland

At Platome Biotechnology we provide scientists with high-quality solutions to grow cells and tissues...

Grant
2-10 employees
Biopharma, Biotechnology
Compare Qkine vs Platome Biotechnology

FAQ About Qkine

High quality and novel growth factors for stem cell and organoid culture, regenerative medicine and cellular agriculture
Qkine was founded in 2016.
Qkine is headquartered in Cambridge, United Kingdom.
Qkine operates in Biotechnology and Life Sciences. Its work centres on Biologically active proteins, Protein purification, Stem cell culture and Regenerative medicine. Its customers include Research institutions, Biotechnology companies and Pharmaceutical companies.
Qkine has approximately 40 employees.
Qkine has completed 5 funding rounds, raising a total of $6.37M. The latest funding stage is Series B.
Qkine offers: Manufacturing bioactive proteins, Developing unique optimized proteins, Sustainable protein production.
Top alternatives and competitors to Qkine include Platome Biotechnology. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Qkine and Platome Biotechnology are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Qkine, https://bouncewatch.com/company/qkine, updated 25 February 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout